Amanote Research
Register
Sign In
MELK Serves as a Potent Independent Biomarker to Predict Survival of Diffuse Large B-Cell Lymphoma Patients Treated With Rituximab-Chop Regimen
Hematological Oncology
- United Kingdom
doi 10.1002/hon.2439_22
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2017
Authors
Y. Zhang
X. Zhou
Y. Li
Y. Xu
X. Wang
Publisher
Wiley